United Therapeutics (UTHR) presents a favorable risk-reward profile ahead of a data readout of Tyvaso in idiopathic pulmonary fibrosis trial in September, Oppenheimer said in a report Monday.
"TETON-2 is a major late-stage catalyst for the IPF space which
has seen many failures," the report said. "Our analysis suggests that shares are currently pricing in ~$65/share for Tyvaso/IPF, far below our estimate, likely assuming a mixed outcome."
A clear positive outcome could push the stock to $450, with a 70% probability, Oppenheimer analysts said, adding that they have "strong conviction" that Tyvaso can beat expectations.
They assigned a 20% likelihood of mixed results, bringing the stock down to $285 per share, implying some 5% downside from current levels, and a 10% likelihood of a clear miss scenario that could bring the stock down about 22%.
Oppenheimer has an outperform rating on the stock with a price target of $510.
Price: 294.71, Change: -0.81, Percent Change: -0.28
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。